XML 54 R29.htm IDEA: XBRL DOCUMENT v3.25.3
Organization and Significant Accounting Policies (Tables)
 12 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Schedule of Company's Current Pipeline
The following table presents the Company’s current pipeline:
Therapeutic AreaNameStageProduct Rights
Cardiometabolic
plozasiran
Phase 3
Arrowhead(1)
zodasiranPhase 3
Arrowhead
olpasiranPhase 3Amgen
ARO-PNPLA3Phase 1Arrowhead
GSK4532990
Phase 2b
GSK
ARO-INHBEPhase 1/2aArrowhead
ARO-ALK7Phase 1/2aArrowhead
ARO-DIMERPA
Phase 1/2a
Arrowhead
PulmonaryARO-RAGEPhase 1/2aArrowhead
SRP-1002 (ARO-MMP7)Phase 1/2aSarepta
LiverfazirsiranPhase 3Takeda and Arrowhead
daplusiran/tomligisiran
Phase 2GSK
NeuromuscularSRP-1001 (ARO-DUX4)Phase 1/2aSarepta
SRP-1003 (ARO-DM1)Phase 1/2aSarepta
SRP-1004 (ARO-ATXN2)Phase 1/2aSarepta
ARO-SNCA
Pre-clinical
Novartis
ARO-MAPT
Phase 1/2a
Arrowhead
OtherARO-C3Phase 1/2aArrowhead
ARO-CFBPhase 1/2aArrowhead
(1) Greater China rights for plozasiran are out-licensed to Sanofi.
Schedule of Useful Lives of Property Plant and Equipment
The estimated useful lives of property, plant and equipment are as follows (in years):
Estimated Useful Lives
Buildings
39
Research equipment
5
Manufacturing equipment
7 to 10
Furniture
7
Computers and software
3 to 5
Leasehold improvements
  Shorter of asset life or lease term
The following table summarizes the Company’s major classes of property, plant and equipment:
September 30,
20252024
(in thousands)
Land$2,996 $2,996 
Buildings
251,317 75,988 
Research equipment62,758 65,353 
Manufacturing equipment
18,588 — 
Furniture5,594 5,594 
Computers and software1,064 981 
Leasehold improvements104,425 104,410 
Construction in progress15,942 188,731 
462,684 444,053 
Less: Accumulated depreciation and amortization(80,169)(58,021)
Property, plant and equipment, net$382,515 $386,032